Empagliflozin improved clinical outcomes in patients with acute heart failure (AHF), regardless of blood pressure (BP) levels, with particularly strong benefits observed in those with diastolic BP ...
Earlier this week, German manufacturer Boehringer Ingelheim’s patent to manufacture Empagliflozin, a medication to treat type 2 diabetes mellitus, expired in India. Empagliflozin is sold under ...
The diabetes care landscape in India is set for a major transformation as domestic pharmaceutical companies reportedly prepare to launch low-cost generic versions of Empagliflozin. The move comes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback